You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ZERIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zerit, and what generic alternatives are available?

Zerit is a drug marketed by Bristol and Bristol Myers Squibb and is included in three NDAs.

The generic ingredient in ZERIT is stavudine. There are fourteen drug master file entries for this compound. Additional details are available on the stavudine profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZERIT?
  • What are the global sales for ZERIT?
  • What is Average Wholesale Price for ZERIT?
Summary for ZERIT
US Patents:0
Applicants:2
NDAs:3
Raw Ingredient (Bulk) Api Vendors: 119
Patent Applications: 5,766
Drug Prices: Drug price information for ZERIT
What excipients (inactive ingredients) are in ZERIT?ZERIT excipients list
DailyMed Link:ZERIT at DailyMed
Drug patent expirations by year for ZERIT
Drug Prices for ZERIT

See drug prices for ZERIT

US Patents and Regulatory Information for ZERIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol ZERIT stavudine CAPSULE;ORAL 020412-001 Jun 24, 1994 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-001 Dec 31, 2002 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol ZERIT stavudine CAPSULE;ORAL 020412-004 Jun 24, 1994 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-002 Dec 31, 2002 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZERIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol ZERIT stavudine CAPSULE;ORAL 020412-001 Jun 24, 1994 ⤷  Sign Up ⤷  Sign Up
Bristol ZERIT stavudine CAPSULE;ORAL 020412-004 Jun 24, 1994 ⤷  Sign Up ⤷  Sign Up
Bristol ZERIT stavudine CAPSULE;ORAL 020412-005 Jun 24, 1994 ⤷  Sign Up ⤷  Sign Up
Bristol ZERIT stavudine FOR SOLUTION;ORAL 020413-001 Sep 6, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ZERIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bristol-Myers Squibb Pharma EEIG Zerit stavudine EMEA/H/C/000110
Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.
Withdrawn no no no 1996-05-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ZERIT

See the table below for patents covering ZERIT around the world.

Country Patent Number Title Estimated Expiration
Egypt 19157 The use of 3- deoxythmiding-2'-ene(3'-deoxy 2-3dedehydrothymidine) in treating patients infected with retroviruses ⤷  Sign Up
Denmark 557087 ⤷  Sign Up
Australia 593405 ⤷  Sign Up
Ireland 873245 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZERIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0273277 SPC/GB96/049 United Kingdom ⤷  Sign Up PRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508
0273277 C960024 Netherlands ⤷  Sign Up PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 - EU/1/96/009/009 19960508
0273277 96C0039 Belgium ⤷  Sign Up PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
0383472 96C0040 Belgium ⤷  Sign Up PRODUCT NAME: STAVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/009/001-009 19960509; FIRST REGISTRATION:
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.